Stock Taper
DMII
DRUGS MADE IN AMERICA ACQUISITION II CORP. ORDINARY SHARES
NASDAQ
$10.14
▲ UP 0.10% (0.01)

KEY STATISTICS

Market Cap$645.92 M
52w High$10.21
52w Low$9.86
Dividend Yield
Frequency
P/E72.43
Volume316
Shares Out.63.70M

COMPANY

LEADERSHIP

Roger Bendelac
CHIEF EXECUTIVE
Roger Bendelac

ABOUT

SECTOR
Financial Services
WENT PUBLIC
December 4, 2025
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
2

PRICE

$10.14 ▲ UP 0.10% (+$0.01)
$10.13$10.13$10.14$10.149:35 AM10:39 AM11:43 AM12:47 PM1:51 PM2:55 PM3:59 PM10.14

About Drugs Made In America Acquisition II Corp. Ordinary Shares

https://dmaacorp.com/ ↗

Drugs Made In America Acquisition II Corp., founded in 2024 in Fort Lauderdale, Florida, aims to execute a business combination through merger, acquisition, recapitalization, or reorganization, as it currently has no significant operations.

INDUSTRY

Financial - Conglomerates

A SERVICE DRUGS MADE IN AMERICA ACQUISITION II CORP. ORDINARY SHARES IS KNOWN FOR

Special Purpose Acquisition Company (SPAC)

Drugs Made In America Acquisition II Corp. is a SPAC aiming to raise capital via IPO to acquire or merge with private pharmaceutical companies, without offering products or services yet.

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity2
Return On Assets4
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score3

INSIDER TRADES

DIRECTOR
Do Catherine
Purchase · 100.0K shares
2025-09-26
DIRECTOR
Shulgan Myron W.
Purchase · 100.0K shares
2025-09-26
DIRECTOR, 10 PERCENT OWNER, OFFICER: CEO AND EXE. CHAIR OF BOARD
Stockwell Lynn
Purchase · 700.0K shares
2025-09-26
DIRECTOR, 10 PERCENT OWNER, OFFICER: CEO AND EXE. CHAIR OF BOARD
Stockwell Lynn
Sale · 8.0M shares
2025-09-26